Clementia Pharmaceuticals' IPO

Clementia Pharmaceuticals raised a round of funding on August 02, 2017. Investors include Public.

Clementia Pharmaceuticals (NASDAQ: CMTA) is a clinical stage biopharmaceutical company that is developing its lead candidate palovarotene, a novel RARĪ³ agonist, to treat Fibrodysplasia Ossificans Pro…

Articles about Clementia Pharmaceuticals' IPO: